Aurobindo Pharma mobilizes to acquire activities and certain assets of Veritaz Healthcare – Udaipur Kiran | Latest news from Udaipur

Aurobindo Pharma is currently trading at Rs. 535.25, up 6.60 points or 1.25% from its previous close of Rs. 528.65 on BSE.

aurobindo pharma obtains usfdas approval for guaifenesin extended release tablets

The certificate opened at Rs. 532.95 and touched a high and a low of Rs. 537.00 and Rs. 528.50 respectively. So far, 8960 shares have been traded over the counter.

BSE Group “A” stock of nominal value Rs. 1 touched a 52-week high of Rs. 1008.75 on 05-Jul-2021 and a 52-week low of Rs. 503.40 on 20-Jun-2022 .

Last week, the high and low of the certificate stood at Rs. 537.00 and Rs. 506.70 respectively. The current market capitalization of the company is Rs. 31274.47 crores.

Sponsors holding the company amounted to 51.83%, while institutions and non-institutions held 38.30% and 9.86% respectively.

Aurobindo Pharma has completed the acquisition of the activities and certain assets of Veritaz Healthcare. Previously, the company received approval from the company’s board of directors for the acquisition of the same.

Veritaz operates in the pharmaceutical industry in India and sells branded generic formulations and other healthcare related products.

Aurobindo Pharma is engaged in the manufacture of pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations such as astemizole, domeperidone and omeprazole; anti-infectives, oral and sterile antibiotics, pain management and osteoporosis segments.